May 29, 2018
Not a day goes by without reading about the major deception caused by the Theranos saga; promising innovative blood tests to patients based on unknown technology backed by million-dollar investments. Now, the consequences will be suffered by the rest of the Silicon Valley Biotech industry; most probably they will be the ones bearing the brunt of this situation with additional regulations (in an industry already extremely regulated) and most importantly cautious future investments for new drug/device development.
“The-Company-Which-Must-Not-Be-Named” is the Exception and not the rule
Read more here: Theranos a Silicon Valley exception rather than a rule